secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000914475-24-000180
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q2 INGREZZA sales $580M (+32% YoY); raises FY guidance; CEO Gorman to retire Oct 11
--------------------------------------------------------------------------------

- INGREZZA Q2 net product sales $580M (+32% YoY); FY 2024 guidance raised to $2.25-$2.3B.
- GAAP net income $65M ($0.63 EPS); Non-GAAP net income $168.9M ($1.63 EPS), vs $125.7M ($1.25) YoY.
- CEO Kevin Gorman to retire Oct 11, 2024; succeeded by Kyle Gano, current Chief Business Development Officer.
- FDA granted Priority Review for crinecerfont in CAH; PDUFA Dec 29 (capsule) and Dec 30 (oral solution) 2024.
- Top-line Phase 2 data for NBI-'568 (schizophrenia) and luvadaxistat (CIAS) on track for Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000180/0000914475-24-000180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000180/nbix-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000914475-24-000180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer